Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia

被引:18
|
作者
Cho, EK
Heo, DS
Seol, JG
Seo, EJ
Chi, HS
Kim, ES
Lee, YY
Kim, BK
Kim, NK
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Haematol Oncol,Canc Res Ctr, Seoul 110744, South Korea
[2] Gachon Med Sch, Gil Med Ctr, Dept Internal Med, Div Haematol Oncol, Inchon, South Korea
[3] Univ Ulsan, Coll Med, Dept Clin Pathol, Seoul, South Korea
[4] Asan Med Ctr, Seoul, South Korea
[5] Han Yang Univ, Coll Med, Dept Internal Med, Div Haematol Oncol, Seoul, South Korea
关键词
chronic myelogenous leukaemia; BCR-ABL rearrangement; fluorescence in situ hybridization; T cells; natural killer cells;
D O I
10.1046/j.1365-2141.2000.02341.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myelogenous leukaemia (CML) is a haematological malignant disorder characterized by the Philadelphia chromosome (Ph) and BCR-ABL gene rearrangement. This abnormal fusion gene can be considered to serve as a marker for the transformed cell clone in CML and is found in all cells arising from the same malignant precursor cell. It has been detected in CML cells of the myeloid, monocytic, erythroid and B-lymphocytic lineages. However, it is still arguable as to whether T lymphocytes or natural killer (NK) cells carry this marker Answering this question would clarify the ontogenic relationship between NE; cells and T cells. We examined 12 CML patients and studied the expression of BCR-ABL rearrangement by fluorescence in situ hybridization (FISH) in both NK cells and T cells sorted by flow cytometry. The purity of T cells was 95.6-99.8% and that of NK cells was 95.3-99.3% after sorting. Neither NK cells nor T cells showed any positive BCR-ABL signal with the exception of one patient who recovered from a lymphoid blastic crisis. We speculate that T cells and NK cells originate from BCR-ABL-negative stem cells.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 50 条
  • [31] Frequency of BCR-ABL Fusion Transcripts in Saudi Patients with Chronic Myelogenous Leukemia
    Elbjeirami, W. M.
    Abdulwahab, A.
    Elsayed, H.
    Elnagdi, N.
    Abd Allatif, N.
    Al-Jedani, H.
    Al Shaikh, A.
    Al-Allaf, F. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 766 - 766
  • [32] Quantification of BCR-ABL mRNA in Plasma/Serum of Patients with Chronic Myelogenous Leukemia
    Narita, Miwako
    Saito, Anri
    Kojima, Aya
    Iwabuchi, Minami
    Satoh, Naoya
    Uchiyama, Takayoshi
    Yamahira, Akie
    Furukawa, Tatsuo
    Sone, Hirohito
    Takahashi, Masuhiro
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2012, 9 (10): : 901 - 908
  • [33] Monitoring of chronic myelogenous leukemia patients by semiquantitative BCR-ABL protein detection in peripheral blood mononuclear cells.
    Schleuning, M
    Mittermüller, J
    Kolb, HJ
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 794 - 794
  • [34] Enhanced and Selective Killing of Chronic Myelogenous Leukemia Cells with an Engineered BCR-ABL Binding Protein and Imatinib
    Constance, Jonathan E.
    Woessner, David W.
    Matissek, Karina J.
    Mossalam, Mohanad
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2012, 9 (11) : 3318 - 3329
  • [35] BCR-ABL MAINTAINS RESISTANCE OF CHRONIC MYELOGENOUS LEUKEMIA-CELLS TO APOPTOTIC CELL-DEATH
    MCGAHON, A
    BISSONNETTE, R
    SCHMITT, M
    COTTER, KM
    GREEN, DR
    COTTER, TG
    BLOOD, 1994, 83 (05) : 1179 - 1187
  • [36] Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
    Vigneri, P
    Wang, JYJ
    NATURE MEDICINE, 2001, 7 (02) : 228 - 234
  • [37] Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft
    Corsetti, MT
    Lerma, E
    Dejana, A
    Cavaliere, M
    Figari, O
    Vassallo, F
    Abate, M
    Luchetti, S
    Piaggio, G
    Parodi, C
    Pira, GL
    Manca, F
    Carella, AM
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (01) : 104 - 111
  • [38] Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
    De Rosa, Viviana
    Monti, Marcello
    Terlizzi, Cristina
    Fonti, Rosa
    Del Vecchio, Silvana
    Iommelli, Francesca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (13):
  • [39] Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells
    Lou, YJ
    Jin, J
    LEUKEMIA & LYMPHOMA, 2004, 45 (02) : 373 - 376
  • [40] MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells
    Kawano, Takeshi
    Ito, Masaki
    Raina, Deepak
    Wu, Zekui
    Rosenblatt, Jacalyn
    Avigan, David
    Stone, Richard
    Kufe, Donald
    CANCER RESEARCH, 2007, 67 (24) : 11576 - 11584